# A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

> **NCT06623890** · — · RECRUITING · sponsor: **Biogen** · enrollment: 300 (estimated)

## Conditions studied

- Friedreich Ataxia

## Interventions

- **DRUG:** Omaveloxolone

## Key facts

- **NCT ID:** NCT06623890
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-12
- **Primary completion:** 2029-10-01
- **Final completion:** 2029-10-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06623890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06623890, "A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06623890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*